Harmony Biosciences announces planned CEO transition to support next phase of growth
HRMY•Harmony Biosciences appointed Peter Anastasiou president, CEO and board member effective Jan. 1, 2027; Jeffrey M. Dayno will retire as CEO and leave the board at year-end 2026. The company reiterated 2026 WAKIX net revenue guidance of $1 billion-$1.04 billion and said it remains on track to report BP-205 MAD study data in Q4 2026.
1. Leadership transition
Harmony Biosciences appointed Peter Anastasiou president, CEO and board member effective Jan. 1, 2027. Jeffrey M. Dayno will retire as CEO and step down from the board at year-end 2026.
2. 2026 outlook
The company reiterated full-year 2026 WAKIX net revenue guidance of $1 billion-$1.04 billion and said it is on track to report BP-205 MAD study data in Q4 2026.
